3rd Next-Generation Conjugates Summit

Memo

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and FormatsTraditional ADCs have seen significant success in recent years, but still face many challenges, from limited payload capacities to significant toxicities. Given these limitations, drug developers are venturing beyond the conventional boundaries of conjugate drug design, by exploring novel payloads and targeting formats, with companies including VincerX Pharma, Dyne Therapeutics, and Orum Therapeutics currently awaiting clinical validation. Join 150+ of your peers to share learnings and collaborate on novel design concepts, key translational and clinical development challenges, and address challenging CMC roadblocks for the next generation of conjugated therapeutics, including antibody-oligonucleotide conjugates, fragment-drug conjugates, antibody-degrader conjugates, small molecule-drug conjugates, and bispecific-drug conjugates and more!   URLs:Tickets: https://go.evvnt.com/2049241-2?pid=5569Brochure: https://go.evvnt.com/2049241-3?pid=5569 Date and Time: On Mon, 26 Feb 2024 08:30 - Wed, 28 Feb 2024 17:00 Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States Prices:Drug Developer Pricing - Conference Only: USD 2999.00,Drug Developer Pricing - Conference + Pre Conference Day: USD 4197.00,Solution Provider - Conference Only: USD 3699.00,Solution Provider - Conference + Pre-Conference Day: USD 5097.00,Academic Pricing - Conference Only: USD 2599.00,Academic Pricing - Conference + Pre-Conference Day: USD 3597.00 Speakers: Amy Han, Executive Director, R AND D Chemistry, Regeneron, Bin Wu, Principal Scientist, Amgen Inc., Chad Miller, Co-Founder and Head of Research, Nosis Biosciences, Charles Chen, Senior Director - Clinical Pharmacology and Translational Sciences, Zymeworks, Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies Inc., Colby Souders, Chief Scientific Officer, BrickBio, Emily Wyent, Senior Director - Research and Development, Dantari, Inc., Graham Cotton, Vice President and Head of Protein Therapeutics, Almac, Gregory Adams, Chief Scientific Officer, Elucida Oncology Inc., Guitao Wang, VP, Coherent Biopharma, Hamid Samareh Afsari, Reagents-Biochemistry And Conjugation Group Lead, Boehringer Ingelheim, Han Kim, In Vivo Pharmacology, Bolt Biotherapeutics, Igor Sherman, Chief Executive Officer and Founder, Alpha Cancer Technologies, Jamie Rich, Senior Director, Technology, Zymeworks, Jan Van Bodegom, Chief Medical Officer, Coretag, Jun Shao, Chief Operating Officer, Zhejiang Hisun Biomaterials Co,Ltd, Lara McGrath, Director - Translational Medicine, AstraZeneca, Leo Marx, Medicinal Chemist and Bioconjugation Manager, Debiopharm Research and Manufacturing SA, Mahendra Deonarain, Chief Executive Officer, Antikor, Mano Manoharan, Senior Vice President, Innovation Chemistry and Alnylam Distinguished Scientist, Alnylam Pharmaceuticals, Marc Damelin, Vice President - Biology, Mersana Therapeutics, Mark Frigerio, Vice President - Chemistry, Bicycle Therapeutics, Melanie Frigault Vice President, Translational Medicine, Vincerx Pharma, Merle Fuchs, Chief Executive Officer and Co-Founder, PRAMOMOLECULAR GmbH, Nathan Tumey, Associate Professor, Binghampton University, Neil Bander, CSO, Convergent Therapeutics, Nicholas Yoder, Senior Director, Platform Development, Dyne Therapeutics, Philipp Spycher, Chief Scientific Officer, Araris Biotech AG, Shalom Goldberg, Senior Principal Scientist, Johnson and Johnson Services, Inc, Stefano Zanotti, Vice President and Head of Neuromuscular Research, Dyne Therapeutics, Vicky Appleman, Principal Scientist, Takeda Pharmaceutical Co. Ltd., Vimal Patel, Vice President, CMC, RadioPharm Theranostics, Xiaoyong, Lu Director, Eli Lilly and Co.